ELB-139

From Self-sufficiency
Jump to: navigation, search
ELB-139
File:ELB-139.png
Systematic (IUPAC) name
1-(4-Chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-one
Identifiers
CAS Number 188116-08-7
PubChem CID 11277418
Chemical data
Formula C14H16ClN3O
Molar mass 277.749 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

ELB-139 (LS-191,811) is an anxiolytic drug with a novel chemical structure, which is used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.[1][2]

ELB-139 is a subtype-selective partial agonist at GABAA receptors, with highest affinity for the α3 subtype, but highest efficacy at α1 and α2.[3] It has primarily anxiolytic and anticonvulsant effects, but produces little sedative effects or ataxia,[4] and has also been demonstrated in rats to increase serotonin levels in the striatum and prefrontal cortex, without affecting dopamine levels.[5] It has been proposed as a possible candidate for a novel non-sedating anxiolytic or anticonvulsant drug for use in humans, but no trials beyond laboratory work in animals have been conducted to date.[6]




References

  1. ↑ Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-one], a new agonist at the benzodiazepine binding site of the GABAA receptor. Journal of Pharmacology and Experimental Therapeutics. 2005 Aug;314(2):717-24. PMID 15860576
  2. ↑ Atack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opinion in Investigational Drugs. 2005 May;14(5):601-18. PMID 15926867
  3. ↑ Rabe H, Kronbach C, Rundfeldt C, Lüddens H. The novel anxiolytic ELB139 displays selectivity to recombinant GABA(A) receptors different from diazepam. Neuropharmacology. 2007 Mar;52(3):796-801. PMID 17087982
  4. ↑ Grunwald C, Rundfeldt C, Lankau HJ, Arnold T, Höfgen N, Dost R, Egerland U, Hofmann HJ, Unverferth K. Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. Journal of Medicinal Chemistry. 2006 Mar 23;49(6):1855-66. PMID 16539371
  5. ↑ Langen B, Rundfeldt C. ELB139 an agonist at the benzodiazepine binding site increases 5-HT in the striatum and prefrontal cortex of rats: a microdialysis study. Pharmacology, Biochemistry and Behaviour. 2007 Jan;86(1):79-85. PMID 17257662
  6. ↑ Whiting PJ. GABA-A receptors: a viable target for novel anxiolytics? Current Opinion in Pharmacology. 2006 Feb;6(1):24-9. PMID 16359919


GABAA PAMs
Others
α2δ VDCC Blockers
5-HT1A Agonists
Azapirones: Buspirone • Gepirone • Tandospirone; Others: Flesinoxan • Oxaflozane
H1 Antagonists
Diphenylmethanes: Captodiame • Hydroxyzine; Others: Brompheniramine • Chlorpheniramine • Pheniramine
CRH1 Antagonists
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Others

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc, drug(N5A/5B/5C/6A/6B/6D)


35px This drug article relating to the nervous system is a stub. You can help ssf by expanding it.
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=ELB-139&oldid=32249"